Bristol‑Myers Squibb Profit Soars as Company Raises Revenue Guidance

Pharmaceutical giant Bristol‑Myers Squibb delivered a strong third‑quarter performance, reporting adjusted earnings of $1.63 per share, outpacing analyst expectations of around $1.51. Revenue rose to $12.2 billion, topping the consensus estimate of $11.8 billion. Buoyed by this momentum, the company has raised its full‑year guidance: total revenue is now projected in the $47.5 billion to $48.0 billion range, up from earlier estimates of $46.5 billion to $47.5 billion. Adjusted earnings per share are expected to land between $6.40 and $6.60, reflecting improved visibility on its growth portfolio. The uptick was driven largely by strength in the company’s “Growth Portfolio” — driven by new treatments in oncology and hematology — while its legacy business continues to face headwinds from generic competition. Investors responded positively, with the firm’s stock jumping in pre‑market trading. #PharmaEarnings #BristolMyersSquibb #GrowthPortfolio #EarningsBeat #SlimScan #GrowthStocks #CANSLIM